Hongyun Wang

Prof. Hongyun Wang

Clinical Pharmacology Research Center, Peking Union Medical College Hospital

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2021 in Clinical Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
FZFan Zhang
Fan Zhang
RJRanran Jia
Ranran Jia
HGHuitao Gao
Huitao Gao
XWXiaofei Wu
Xiaofei Wu
BLBo Liu
Bo Liu
HWHongyun Wang
Hongyun Wang

1 February 2021 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
FZFan Zhang
Fan Zhang
YZYinping Zhou
Yinping Zhou
NWNi Wu
Ni Wu
RJRanran Jia
Ranran Jia
ALAijing Liu
Aijing Liu
HWHongyun Wang
Hongyun Wang

1 January 2025 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
ZWZiyang Wang
Ziyang Wang
WXWen Xu
Wen Xu
DLDan Liu
Dan Liu
XLXiuqi Li
Xiuqi Li
SLShupeng Liu
Shupeng Liu
HWHongyun Wang
Hongyun Wang
Food-Drug Interaction (FDI) refers to the phenomenon where food affects the pharmacokinetic or pharmacodynamic characteristics of a drug, significantly altering the drug’s absorption rate or absorption extent. These Interactions are considered as a primary determinant in influencing the bioavailability of orally administered drugs within the gastrointestinal tract. The impact of food on drug absorption is complex and multifaceted, potentially involving alterations in gastrointestinal physiology, increases in splanchnic blood flow rates, and shifts in the gut microbiota’s composition. Up to now, extensive research has focused on the interactions between food composition (such as proteins, fats, and vitamins) and drug absorption. In contrast, the impact of food physical properties (such as viscosity, volume, and pH) has received less attention in drug development. This article reviewed the impact of food properties on oral drug absorption based on a comprehensive literature search, focusing on the influence of food volume and food viscosity. From the perspective of pharmacokinetics, we examined interaction trends between food properties and drugs across different classification based on the Biopharmaceutics Classification System (BCS). In addition, we introduced the practical application of physiologically based pharmacokinetic (PBPK) modeling in predicting oral drug absorption under the influence of food Properties. Plain Language Summary: In the development of new drugs, understanding how food affects drug absorption is crucial. Although scientists have deeply studied the role of food components–such as proteins, fats, and carbohydrates–in drug absorption, the impact of food’s physical properties, like viscosity, volume, and temperature, on drug safety is often overlooked. Dietary differences across cultures, such as the sticky porridge and steamed buns in China versus bread and milk in the West, suggest that food properties may differentially affect drug absorption. We emphasize the key role of food properties in drug absorption and review how these properties influence gastrointestinal function and drug bioavailability. Additionally, we discuss the specific interactions between different types of drugs and food properties, emphasizing the importance of incorporating food properties into the construction of drug absorption models.

29 August 2018 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
FYFen Yang
Fen Yang
MJMin Jiang
Min Jiang
MLMing Lu
Ming Lu
PHPei Hu
Pei Hu
HWHongyun Wang
Hongyun Wang
JJJi Jiang
Ji Jiang
Objective: This phase Ia study was designed to assess the pharmacokinetic (PK) characters of free vincristine (F-VCR, refer to as non-liposomal VCR and VCR released from liposome) and total vincristine (T-VCR, the sum of both liposomal VCR and F-VCR), urinary excretion and safety of intravenous administration of vincristine sulfate liposomes injection (VSLI) in Chinese patients with malignant lymphoma and compare the results with those for conventional vincristine sulfate injection (VSI). Methods: In the phase Ia, randomized, open-label, two sequence cross-over study, patients from one group were exposed to treatment 1 including cytoxan (cyclophosphamide power injection), hydroxyrubicin (adriamycin power injection), oncovin (VSI), and prednisone tablets (standard CHOP scheme) before crossed over to treatment 2 (modified CHOP scheme in which VSI was replaced with VSLI). Patients from another group received treatments in reverse order. Results: In this phase Ia study, a total of eight subjects participated. VCR elimination from the circulation after injection of VSLI was characterized by a significantly increased maximum concentration (Cmax, 86.6 ng/mL) and plasma area under the plasma concentration-time curve from zero to infinity (AUC0-Inf, 222.1 ng/mL h), markedly decreased distribution volume (Vz, 224.1 L) and plasma clearance (CL, 8.9 L/h) compared to lower Cmax (26.6 ng/mL) and AUC0-Inf (95.1 ng/mL h), larger Vz (688.8 L) and CL (22.1 L/h) for VSI. The small proportion of F-VCR following infusion of VSLI in circulation was reflected by very low Cmax (1.8 ng/mL) and AUC0-Inf (50.5 ng/mL h). Less than 3% of the administered dose of VSLI was excreted in urine and the extent was similar to that for VSI. The elimination percentage of 40–21–14% for VSI changed to 6.2–24–39% for VSLI at intervals of 0–5, 5–13 and 13–25 h, respectively. Significant difference of toxicity between VSLI and VSI was not observed. Conclusion: VSLI exhibits higher AUC0-Inf of T-VCR, lower CL and Vz compared with VSI. VSLI was well tolerated, maybe due to the markedly decreasing AUC0-Inf of F-VCR. The majority of VCR was enveloped in liposome and VCR was released gradually from liposome following injection of VSLI. Liposomal encapsulation of VCR does not alter the route and extent of VCR excretion in urine.

1 June 2019 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
QZQuankun Zhuang
Quankun Zhuang
XLXuemei Liu
Xuemei Liu
ZSZhuo Sun
Zhuo Sun
HWHongyun Wang
Hongyun Wang
JJJi Jiang
Ji Jiang

4 June 2018 in Bioanalysis
Verified
Journal Article
Closed access
XLXuemei Liu
Xuemei Liu
RCRui Chen
Rui Chen
GZGuanghuai Zeng
Guanghuai Zeng
YGYing Gao
Ying Gao
XLXiuping Liu
Xiuping Liu
JJJi Jiang
Ji Jiang
Aim: Hemay005 is a novel small-molecule inhibitor of phosphodiesterase-4 developed for the treatment of psoriasis. Measurement of Hemay005 in biological samples is critical for evaluation of its pharmacokinetics in clinical studies. Methodology & results: Plasma and urine samples were extracted and then chromatographed on an Acquity UPLC HSS T3 column with a gradient elution. Detection was performed on a Xevo TQ-S tandem mass spectrometer using negative ESI. Conclusion: For the first time, a sensitive and robust ultra-high performance liquid chromatography–tandem mass spectrometry (UPLC–MS/MS) method was established and validated for the quantitative determination of Hemay005 in human plasma and urine, and it was successfully applied to evaluate the pharmacokinetics of Hemay005 in healthy subjects in a first-in-human study.